Cancer-fighting immune cells

The term "Cancer-fighting immune cells" is not a specific molecular target or receptor, but rather a broad, non-specific phrase referring to several types of immune cells that play key roles in recognizing and destroying cancer cells. The most prominent among these are cytotoxic T lymphocytes (CD8+ T cells), natural killer (NK) cells, and sometimes invariant NK T (iNKT) cells. These cell types can directly kill tumor cells through mechanisms such as the release of perforin and granzymes leading to apoptosis, engagement of death receptors via ligands like FasL or TRAIL, and secretion of cytokines including interferon-gamma[1][4][7]. Helper CD4+ T cells also support anti-tumor immunity by producing cytokines that enhance the activity of other immune effectors[4][8]. Immunotherapies—including checkpoint inhibitors, CAR-T cell therapies, monoclonal antibodies, and cancer vaccines—are designed to harness or augment the activity of these cancer-fighting immune cell populations[2][3][5]. However, "Cancer-fighting immune cells" is not itself a single molecule or receptor; it refers collectively to multiple cellular components within the adaptive and innate arms of the immune system involved in anti-cancer responses. Because this entry does not refer to a specific molecule or defined therapeutic target but instead describes a heterogeneous group with diverse functions and mechanisms across different contexts in oncology research and therapy development, it should be flagged as incorrect for structured database purposes.